Treatment of acute myelogenous leukaemia in patients aged 50-65: idarubicin is more effective than zorubicin for remission induction and prolonged disease-free survival can be obtained using a unique consolidation course
- 1 August 1996
- journal article
- clinical trial
- Published by Wiley in British Journal of Haematology
- Vol. 94 (2) , 333-341
- https://doi.org/10.1046/j.1365-2141.1996.d01-1803.x
Abstract
No abstract availableKeywords
This publication has 0 references indexed in Scilit: